CELG~

Submission status for CELGENE CORP's drug REBLOZYL (SUPPL-10) with active ingredient LUSPATERCEPT-AAMT has changed to 'Approval' on 05/16/2024. Application Category: BLA, Application Number: 761136, Application Classification:

Submission status for CELGENE CORP's drug REBLOZYL (SUPPL-9) with active ingredient LUSPATERCEPT-AAMT has changed to 'Approval' on 08/28/2023. Application Category: BLA, Application Number: 761136, Application Classification:

Submission status for CELGENE CORP's drug REBLOZYL (SUPPL-6) with active ingredient LUSPATERCEPT-AAMT has changed to 'Approval' on 07/08/2022. Application Category: BLA, Application Number: 761136, Application Classification:

Submission status for CELGENE CORP's drug IDHIFA (SUPPL-5) with active ingredient ENASIDENIB MESYLATE has changed to 'Approval' on 07/26/2021. Application Category: NDA, Application Number: 209606, Application Classification: Manufacturing (CMC)

For Immediate Release: March 27, 2021 The U.S. Food and Drug Administration approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to treat adult patients with multiple myeloma who have not responded to, or whose disease has returned after, at least four prior lines (different types) of therapy. Abecma is the first cell-based gene therapy approved by the FDA for the treatment of multiple myeloma. “The FDA remains committed to ad

SOUTH SAN FRANCISCO, Calif., Dec. 1, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced that Jon M. Wigginton, M.D., has been appointed to Sutro's Board of Directors. "As a seasoned global pharmaceutical leader with a passion for drug development and expertise in oncology, Jon brings a wealth of experience to the Board," said Bill Newell, Sutro's Chief Executive Officer. "His impressive successes in leading programs and bridging basic science, translational

SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics,  announced today that it will host a live webcast event to provide a clinical update from the company's ongoing dose escalation Phase 1 study of STRO-002, a folate receptor alpha (FolRα) targeting antibody-drug conjugate (ADC), for patients with ovarian cancer. The results presented will follow-up on previously presented data, based on a new data cut-off date of Oct. 30, 2020. The compa

SEATTLE--(BUSINESS WIRE)--The cells of the body are made up of the same basic components, namely: Blood, Muscle, Nerve, Brain, Gut, Respiratory, Skin, Cardiovascular, Urine, and Stem Cells. Each of these cells is unique in its characteristics but all of them play an important role in how healthy your body is and how well it functions. Blood cells are made up of red blood cells (erythrocytes), platelets (platelet-activating factor) and neutrophils (killer T cells). Unlike blood cells in other organs of the body, white blood cells (white blood cells) do not multiply: they only act as a defense mechanism for the body in the fight against infection and in keeping your immune system a